Inhibiting or knocking MET down made colon cancer cells sensitive on cetuximab-mediated growth inhibition, implicating that targeting MET was a rational strategy for reversing cetuximab resistance in colon cancer [42]. The gene discussed is MET; the disease is colonic neoplasm.